(S1 (S (S (NP (NP (NN RNA) (NN damage)) (CC and) (NP (NP (NN inhibition)) (PP (IN of) (NP (JJ neoplastic) (JJ endothelial) (NN cell) (NN growth))))) (: :) (NP (NP (NNS effects)) (PP (IN of) (NP (ADJP (ADJP (JJ human)) (CC and) (ADJP (JJ amphibian))) (NNS ribonucleases))))) (. .)))
(S1 (S (S (NP (NN Angiogenesis)) (VP (VBZ defines) (NP (NP (DT the) (JJ many) (NNS steps)) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (NP (NP (NN growth)) (CC and) (NP (NN migration)))) (PP (IN of) (NP (JJ endothelial) (JJ cell-derived) (NN blood) (NNS vessels))))))))) (. .)))
(S1 (S (S (S (NP (DT This) (NN process)) (VP (VBZ is) (ADJP (JJ necessary) (PP (IN for) (NP (NP (DT the) (NP (NP (NN growth)) (CC and) (NP (NN metastasis)))) (PP (IN of) (NP (NNS tumors)))))))) (, ,) (CC and) (S (NP (JJ considerable) (NN effort)) (VP (VBZ is) (VP (VBG being) (VP (VBN expended) (S (VP (TO to) (VP (VB find) (NP (NP (NNS inhibitors)) (PP (IN of) (NP (NN tumor) (NN angiogenesis)))))))))))) (. .)))
(S1 (S (S (NP (DT This)) (ADVP (RB usually)) (VP (VBZ involves) (NP (NP (NN screening)) (PP (IN of) (NP (JJ potential) (JJ anti-angiogenic) (NNS compounds))) (PP (IN on) (NP (JJ endothelial) (NNS cells)))))) (. .)))
(S1 (S (S (PP (TO To) (NP (DT this) (NN end))) (, ,) (NP (NP (CD two) (NN candidate) (JJ anti-angiogenic) (JJ RNA-damaging) (NNS agents)) (, ,) (NP (NP (NN onconase)) (CC and) (NP (NN -LRB--4-RRB-rhEDN))) (, ,)) (VP (VBD were) (VP (VBN screened) (PP (IN for) (NP (NP (PRP$ their) (NNS effects)) (PP (IN on) (NP (JJ endothelial) (NN cell) (NN proliferation))))) (S (VP (VBG using) (NP (NP (CD three) (JJ distinct) (NNS types)) (PP (IN of) (NP (NP (NP (JJ endothelial) (NNS cells)) (PP (IN in) (NP (NN culture)))) (: :) (NP (NP (NN HPV-16) (JJ E6/E7-immortalized) (JJ human) (JJ umbilical) (NN vein) (JJ endothelial) (NNS cells)) (PRN (-LRB- -LRB-) (NP (NNS HUVECs)) (-RRB- -RRB-))) (, ,) (NP (NP (DT a) (JJ Kras-transformed) (NN HPV-16) (NN E6/E7) (NN HUVEC)) (PRN (-LRB- -LRB-) (NP (NNP Rhim) (FW et) (FW al.) (, ,) (NP (NN Carcinogenesis) (CD 4)) (, ,) (NP (CD 673-681)) (, ,) (NP (CD 1998))) (-RRB- -RRB-))) (, ,) (CC and) (NP (JJ primary) (NNS HUVECs)))))))))) (. .)))
(S1 (S (S (NP (NN Onconase)) (ADVP (RB similarly)) (VP (VBD inhibited) (NP (NN proliferation)) (PP (IN in) (NP (NP (DT all) (CD three) (NN cell) (NNS lines)) (PRN (-LRB- -LRB-) (NP (NN IC-LRB-50-RRB-) (JJ =) (CD 0.3-1.0) (NN microM)) (-RRB- -RRB-)))) (SBAR (IN while) (S (NP (NN -LRB--4-RRB-rhEDN)) (VP (VBD was) (ADJP (ADJP (RBR more) (JJ effective) (PP (IN on) (NP (VBN immortalized) (NN HUVEC) (NN cell) (NNS lines)))) (PRN (-LRB- -LRB-) (NP (NN IC-LRB-50-RRB-) (JJ =) (CD 0.02-0.06) (NN microM)) (-RRB- -RRB-))) (PP (IN than) (PP (IN on) (NP (NP (JJ primary) (NNS HUVECs)) (PRN (-LRB- -LRB-) (NP (CD IC-LRB-50-RRB-) (NN >) (CD 0.1) (NN microM)) (-RRB- -RRB-)))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Differential) (NN sensitivity)) (PP (TO to) (NP (DT these) (NNS agents)))) (VP (VBZ implies) (SBAR (IN that) (S (NP (QP (JJR more) (IN than) (CD one)) (JJ endothelial) (NN cell) (NN type)) (VP (MD must) (VP (VB be) (VP (VBN used) (PP (IN in) (NP (NN proliferation) (NNS assays))) (S (VP (TO to) (VP (VB screen) (PP (IN for) (NP (JJ novel) (JJ anti-angiogenic) (NNS compounds))))))))))))) (. .)))
